UK Markets closed

Cannovum AG expands cannabis wholesale license and enters the active ingredient market

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

DGAP-News: Cannovum AG / Key word(s): Regulatory Approval
28.09.2021 / 09:00
The issuer is solely responsible for the content of this announcement.

Cannovum AG (Düsseldorf, Munich, Hamburg, Berlin stock exchanges, gettex: ISIN DE000A2LQU21) is expanding its wholesale license through its subsidiary, Cannovum Health eG. The expansion includes the active ingredient license, which enables the trading of active pharmaceutical ingredients. Cannovum is now authorized to distribute dronabinol, the first cannabis-based active ingredient, to pharmacies.

Active pharmaceutical ingredients are the components of a medication that are responsible for its efficacy. They trigger the essential biochemical process that ensures the medication acts in a specific way in the human body. One of the most important active ingredients of cannabis is THC, which is considered to have the greatest pharmaceutical potential and therapeutic efficacy.

Cannovum's scientific sales force has undergone intensive training with medical professionals, including for the new THC active ingredients, to assist physicians and pharmacists with individual cannabis-based therapies.

With the active ingredient license, Cannovum can now deal with active pharmaceutical ingredients in general and is not limited to dronabinol. In addition, Cannovum already holds the pharmaceutical wholesale licenses, including the GMP license required to map manufacturing steps in Germany.

"We want to improve patient care and that's why we decided to add active substances to our portfolio. Active ingredients are the core element of every medication and indispensable in the effective therapy of patients. We want to give physicians the opportunity to find an effective individual treatment for each of their patients, because every patient deserves the best therapy," says Pia Marten, CEO of Cannovum AG.


28.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Cannovum AG

Rheinsberger Str. 76/77

10115 Berlin

Germany

Phone:

+49 (0)30 3982 16360

E-mail:

ir@cannovum.com

Internet:

www.cannovum.com

ISIN:

DE000A2LQU21

WKN:

A2LQU2

Listed:

Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich

EQS News ID:

1236360


 

End of News

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting